Your browser doesn't support javascript.
loading
Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
Elnair, Radowan; Ellithi, Moataz; Kallam, Avyakta; Shostrom, Valerie; Bociek, Robert G.
Afiliação
  • Elnair R; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA. radowan.elnair@unmc.edu.
  • Ellithi M; Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Vermillion, SD, USA.
  • Kallam A; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  • Shostrom V; College of Public Health, Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
  • Bociek RG; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Ann Hematol ; 100(10): 2513-2519, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34279675
ABSTRACT
Richter's transformation (RT) is a rare complication arising in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is associated with an overall dismal outcome. The rarity of this entity poses many challenges in understanding its biology and outcomes seen and the optimal treatment approach. We utilized the SEER (Surveillance, Epidemiology and End Results) database to identify patients diagnosed with CLL/SLL between 2000 and 2016 and subsequently had a diagnosis of diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL), thus capturing those who experienced an RT event. We compared the outcomes of those patients to those of patients in the database diagnosed with DLBCL without a preceding CLL/SLL diagnosis. We identified 530 patients who developed RT out of 74,116 patients diagnosed with CLL/SLL in the specified period. The median age at RT diagnosis was 66 years, and the median time from CLL/SLL diagnosis to RT development was roughly 4 years. Patients with RT had a dismal outcome with median overall survival of 10 months. We identified advanced Ann Arbor stage (III/IV) and prior treatment for CLL as predictors of worse outcome in patients with RT. Our study represents the largest dataset of patients with CLL/SLL and RT and adds to the existing literature indicating the poor outcomes for those patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos